Dicerna Pharmaceuticals Announces Second DsiRNA Therapeutic Oncology Candidate, Achieves Development Milestone
08:30 EDT 8 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Dicerna
Pharmaceuticals Inc., a second generation RNA interference (RNAi)
company developing novel therapeutics utilizing its proprietary Dicer
Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules,
announc...
Other Sources for this Article
Dicerna Pharmaceuticals
Douglas M. Fambrough, Ph.D., 617-612-6205
CEO
or
Pure
Communications
Michele Rozen, 617-730-8284
More From BioPortfolio on "Dicerna Pharmaceuticals Announces Second DsiRNA Therapeutic Oncology Candidate, Achieves Development Milestone"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
